Aphexda (motixafortide)
Research Synopsis
- - * Aphexda (motixafortide) is a novel chemokine antagonist that selectively inhibits the CXCR4 receptor, which is critical for mobilizing hematopoietic stem cells (HSCs) in medical therapies.
- - * Recent studies have shown that motixafortide, in combination with G-CSF, significantly increases the mobilization of HSCs for autologous stem cell transplantation in multiple myeloma patients, outperforming placebo controls.
- - * The drug received FDA approval on September 11, 2023, specifically for use alongside filgrastim in patients with multiple myeloma.
- - * Ongoing research is investigating the effectiveness of motixafortide in treating pancreatic cancer and acute myeloid leukemia, where it has Orphan Drug Designation.
- - * The COMBAT/KEYNOTE-202 trial highlighted a 21.1% objective response rate when motixafortide was combined with pembrolizumab and chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC), indicating its therapeutic potential in difficult-to-treat cancers.
- - * A comparative review noted that while motixafortide shows better pharmacokinetics than the older mobilizing agent plerixafor, overall effectiveness in clinical trials may be similar, which could affect its practical use due to cost considerations.
- - * Research has elucidated the structural interactions of motixafortide with the CXCR4 receptor, providing insights necessary for future development of effective CXCR4 inhibitors.
- - * Overall, the sentiment surrounding motixafortide is positive, given its promising results in both hematopoietic stem cell mobilization and combined cancer therapies, while recognizing the need for further studies on long-term efficacy and safety.
- - * Motixafortide is being tested in various settings, including potential roles in gene therapy for sickle cell disease, emphasizing its broad application in hematological treatments.
- - * The understanding of the CXCR4/CXCL12 signaling axis is continuously evolving, underlining the importance of motixafortide as both a standalone therapy and as part of combination treatments for enhancing patient outcomes.
Aphexda (motixafortide)
Clinical significance of chemokine receptor antagonists.
London, UK
2 hours ago
1 Received
- * Approved antagonists include plerixafor for stem cell mobilization, maraviroc for HIV, and mogamulizumab for certain skin cancers; these have established clinical uses.
- * Current trials are exploring additional candidates, with efficacy relying on efficiently blocking specific chemokine receptors crucial for disease development.
$100 - $150
Hourly Rate
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
London, UK
2 hours ago
1 Received
- The study investigates the effects of a CXCR4 inhibitor (BL-8040) in combination with PD-1 therapy (pembrolizumab) and chemotherapy on metastatic pancreatic ductal adenocarcinoma (PDAC), aiming to improve treatment outcomes for this challenging cancer type.
- In the first cohort (37 patients), the combined treatment showed a disease control rate of 34.5% with a median overall survival of 3.3 months, while a subgroup receiving it as second-line therapy had a notable median overall survival of 7.5 months.
- The second cohort (22 patients) exhibited improved response rates, with an objective response rate of 32% and a disease
$100 - $150
Hourly Rate
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
London, UK
2 hours ago
1 Received
- * Alterations in the CXCR4/CXCR7-CXCL12 axis are linked to several diseases, including cancer and autoimmune conditions, which suggests its importance in disease progression and treatment.
- * Despite promising clinical modulators for CXCR4 and CXCL12 already in development, research on CXCR7 modulators is limited, indicating a need for further studies in this area.
$100 - $150
Hourly Rate
At the Bedside: Profiling and treating patients with CXCR4-expressing cancers.
London, UK
2 hours ago
1 Received
- The C-X-C chemokine receptor type 4 (CXCR4) and its ligand play crucial roles in blood cell trafficking, tumor growth, and metastasis for over 20 years.
- Plerixafor is the only FDA-approved CXCR4 inhibitor, but several new inhibitors are in clinical trials showing promise against various tumors.
- Molecular imaging and radiolabeled theranostics are being explored to enhance therapy effectiveness and patient selection for those with CXCR4-expressing cancers.
$100 - $150
Hourly Rate
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
London, UK
2 hours ago
1 Received
- The study investigates the effects of combining motixafortide, pembrolizumab, and chemotherapy on patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have not responded to previous gemcitabine-based treatment.
- A total of 43 patients participated, showing a 21.1% objective response rate and a median progression-free survival of 3.8 months, indicating some effectiveness of the treatment.
- The combination therapy was found to be safe, with low instances of severe side effects, demonstrating promise for a challenging cancer type that typically has limited treatment options.
$100 - $150
Hourly Rate
MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?
London, UK
2 hours ago
1 Received
- Chemokines, a type of cytokine, play crucial roles in immune responses during processes like tissue repair and inflammation, particularly through their receptors like CXCR4.
- CXCR4, activated by its ligand SDF-1, triggers multiple signaling pathways that impact various cellular functions and is notably expressed in many tumors.
- MSX-122 is highlighted as an effective oral CXCR4 antagonist with significant potential in treating metastatic cancers, along with other CXCR4 blockers being explored in cancer therapy research.
$100 - $150
Hourly Rate
Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.
London, UK
2 hours ago
1 Received
- Modulation of the CXCL12-CXCR4 signaling axis is crucial for understanding its role in diseases like cancer and inflammation, with motixafortide being a leading drug that shows promise in treating various cancers.
- Despite its potential, the exact mechanism of how motixafortide interacts with the CXCR4 receptor remains unclear, prompting a study using computational techniques to analyze this relationship.
- The findings reveal that motixafortide stabilizes inactive states of CXCR4 through specific interactions between its cationic residues and CXCR4's acidic residues, providing insights for the future design of effective CXCR4 inhibitors.
$100 - $150
Hourly Rate
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
London, UK
2 hours ago
1 Received
- Autologous hematopoietic stem cell transplantation (ASCT) can improve survival rates in multiple myeloma (MM), but some patients struggle to collect enough HSPCs using standard methods like G-CSF.
- The GENESIS trial tested a new drug, motixafortide, combined with G-CSF, against a placebo and G-CSF to see if it could help mobilize more HSPCs for ASCT.
- Results showed that motixafortide significantly increased the number of patients who collected sufficient HSPCs, outperforming the placebo group, and its side effects were generally mild and manageable.
$100 - $150
Hourly Rate
Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide.
London, UK
2 hours ago
1 Received
- Hematopoietic stem-cell transplantation (HCT) and gene therapies depend on collecting enough CD34+ hematopoietic stem and progenitor cells (HSPCs) from the blood, usually via various mobilization regimens involving agents like G-CSF and plerixafor.
- Traditional mobilization methods often require multiple days of injections and procedures, sometimes resulting in insufficient amounts of HSPCs needed for gene-edited therapies.
- Motixafortide, a new CXCR4 inhibitor, shows promise in mobilizing greater numbers of high-quality HSPCs quickly and safely, providing a potential improvement over current methods, especially for patients with conditions like sickle-cell disease.
$100 - $150
Hourly Rate
Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Motixafortide: First Approval.
London, UK
2 hours ago
1 Received
- Motixafortide (APHEXDA) is a targeted drug that inhibits the CXCR4 receptor, aimed at mobilizing hematopoietic stem cells (HSCs) and treating various cancers.
- On September 11, 2023, it received approval in the US for use with filgrastim to mobilize HSCs for patients with multiple myeloma.
- The drug has Orphan Drug Designation for pancreatic cancer and acute myeloid leukemia, and ongoing clinical trials are focusing on its use in gene therapy for sickle cell disease.
$100 - $150
Hourly Rate
Correction to: Motixafortide: First Approval.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Motixafortide Acetate.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.
London, UK
2 hours ago
1 Received
- In 2023, the FDA approved nine TIDES, including four oligonucleotides targeting disorders like ALS, geographic atrophy, primary hyperoxaluria type 1, and hereditary transthyretin-mediated amyloidosis, all with enhanced stability and effectiveness.
- The approved peptides exhibit a variety of structures (linear, cyclic, and lipopeptides) and applications, including the first orphan drug designation for a peptide-based chemokine antagonist.
- Notably, a peptide-based treatment was approved for core symptoms of Rett syndrome, with the analysis of TIDES focusing on their chemical structure, medical targets, and potential side effects.
$100 - $150
Hourly Rate
Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).
London, UK
2 hours ago
1 Received
- The incidence of multiple myeloma (MM) is increasing, and while new treatments have improved outcomes, the disease remains incurable; understanding the chemokine network's role in MM could lead to better biomarkers and therapies.
- This research reviews the complex roles of various chemokines in MM, identifying which can be used as biomarkers and exploring potential treatments that target these chemokines.
- Findings suggest that some chemokines help cancer cells evade treatment while others can enhance immune responses; new therapeutic strategies, including anti-tumor chemokines and combinations with CAR-T therapy, show promise for future clinical use.
$100 - $150
Hourly Rate
CXCR4 as a therapeutic target in acute myeloid leukemia.
London, UK
2 hours ago
1 Received
- Extensive research has focused on the CXCL12-CXCR4 axis in acute myeloid leukemia (AML), leading to the development of new anti-leukemia drugs targeting this pathway.
- The review highlights the axis's role in cancer progression, covering its influence on growth, resistance to treatment, and interactions with other cell types like MSCs and T cells.
- It also discusses the clinical implications of the CXCL12-CXCR4 axis, including its connections to prognosis and specific mutations, as well as examining various drugs that target this axis and their therapeutic potential in AML.
$100 - $150
Hourly Rate
A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.
London, UK
2 hours ago
1 Received
- High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the go-to treatment for newly diagnosed multiple myeloma patients, leading to better survival rates.
- Current methods for mobilizing stem cells include using G-CSF alone or with plerixafor; motixafortide is a new option approved for use with G-CSF.
- Although motixafortide shows better pharmacokinetics than plerixafor, their effectiveness is similar in trials, and motixafortide's higher cost and more demanding administration may limit its use in practice.
$100 - $150
Hourly Rate
FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond.
London, UK
2 hours ago
1 Received
- - Peptides are gaining importance in the pharmaceutical industry due to their specific interactions with treatment targets, offering potential therapies for various challenging diseases, with several approved by the FDA.
- - Trofinetide (Daybue), the first cure for Rett syndrome, and motixafortide (Aphexda), a novel chemokine antagonist, showcase the advancements in peptide-based medications.
- - The analysis will focus on FDA-approved peptides for conditions like cardiovascular diseases, HIV, and other diseases, detailing their chemical structures, uses, development history, and possible side effects.
$100 - $150
Hourly Rate